KAT2B and hepatocellular carcinoma: In hepatocellular carcinomas, reduction in TET2 and thereby 5hmC induced chemotherapeutic resistance through the inhibition of histone acetyltransferase P300/CBP-associated factor (PCAF) and hyperactivation of the AKT pathway [29].